JP2001515505A - 軸索再生を促進する単核貪食細胞及びその使用 - Google Patents

軸索再生を促進する単核貪食細胞及びその使用

Info

Publication number
JP2001515505A
JP2001515505A JP54028998A JP54028998A JP2001515505A JP 2001515505 A JP2001515505 A JP 2001515505A JP 54028998 A JP54028998 A JP 54028998A JP 54028998 A JP54028998 A JP 54028998A JP 2001515505 A JP2001515505 A JP 2001515505A
Authority
JP
Japan
Prior art keywords
cells
mononuclear
mononuclear phagocytic
phagocytic cells
monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54028998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515505A5 (enExample
Inventor
アイゼンバック−シュワルツ，マイケル
スピーグラー，オルリー
Original Assignee
イエダ リサーチ アンド ディベロプメント カンパニー．リミテッド．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/818,818 external-priority patent/US6117424A/en
Application filed by イエダ リサーチ アンド ディベロプメント カンパニー．リミテッド． filed Critical イエダ リサーチ アンド ディベロプメント カンパニー．リミテッド．
Publication of JP2001515505A publication Critical patent/JP2001515505A/ja
Publication of JP2001515505A5 publication Critical patent/JP2001515505A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP54028998A 1997-03-14 1998-03-13 軸索再生を促進する単核貪食細胞及びその使用 Ceased JP2001515505A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/818,818 1997-03-14
US08/818,818 US6117424A (en) 1995-09-15 1997-03-14 Compositions of mononuclear phagocytes useful for promoting axonal regeneration
US09/041,280 US6267955B1 (en) 1995-09-15 1998-03-11 Mononuclear phagocytes and their use to promote axonal regeneration
US09/041,280 1998-03-11
PCT/IL1998/000120 WO1998041220A1 (en) 1997-03-14 1998-03-13 Mononuclear phagocytes and their use to promote axonal regeneration

Publications (2)

Publication Number Publication Date
JP2001515505A true JP2001515505A (ja) 2001-09-18
JP2001515505A5 JP2001515505A5 (enExample) 2005-11-10

Family

ID=26717980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54028998A Ceased JP2001515505A (ja) 1997-03-14 1998-03-13 軸索再生を促進する単核貪食細胞及びその使用

Country Status (8)

Country Link
US (1) US6267955B1 (enExample)
EP (1) EP0966292A1 (enExample)
JP (1) JP2001515505A (enExample)
AU (1) AU731086B2 (enExample)
CA (1) CA2283891A1 (enExample)
IL (1) IL131888A0 (enExample)
NZ (1) NZ337813A (enExample)
WO (1) WO1998041220A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523199A (ja) * 2003-03-28 2006-10-12 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 末梢神経疾患の治療及び／又は予防のためのクラステリンの使用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785135B1 (fr) 1998-10-22 2000-12-29 Sfr Sa Procede de lancement d'une application par un terminal, sous commande d'un module d'identification d'abonne, module d'identification d'abonne et terminal correspondants
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP3607271B2 (ja) * 2001-03-12 2005-01-05 株式会社Ｇｂｓ研究所 神経損傷の治療薬
AU2002309987A1 (en) * 2001-05-25 2002-12-09 Hill-Rom Services, Inc. Modular patient room
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
EP1578199A2 (en) * 2002-06-14 2005-09-28 Yeda Research And Development Company, Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US20090010873A1 (en) * 2004-11-29 2009-01-08 Yeda Research And Development Co. Ltd. Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
CA2737193A1 (en) * 2008-09-12 2010-03-18 Universidade Federal De Sao Paulo - Unifesp Ischemic tissue cell therapy
US20120093914A1 (en) 2008-11-24 2012-04-19 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
BR112015029299A2 (pt) 2013-05-22 2017-07-25 Yeda Res & Dev subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares
CN109963940A (zh) * 2016-09-02 2019-07-02 宝生物工程株式会社 从多能干细胞获得小胶质细胞的方法
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
EP4499117A1 (en) * 2022-03-30 2025-02-05 MDX Management LLC Compositions and methods for activating immune cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157024A (en) 1977-10-16 1992-10-20 Strategic Medical Research Corporation Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals
IL71440A0 (en) 1984-04-04 1984-07-31 Univ Ramot Composition for nerve regeneration
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
IL97365A0 (en) 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
IL91459A0 (en) 1989-08-28 1990-04-29 Yeda Res & Dev Oligodendrocyte inhibitory factor
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
IL116922A0 (en) 1996-01-26 1996-05-14 Yeda Res & Dev Compositions for the regeneration of nerves in the central nervous system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523199A (ja) * 2003-03-28 2006-10-12 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 末梢神経疾患の治療及び／又は予防のためのクラステリンの使用

Also Published As

Publication number Publication date
NZ337813A (en) 2002-04-26
AU731086B2 (en) 2001-03-22
US6267955B1 (en) 2001-07-31
AU6634398A (en) 1998-10-12
EP0966292A1 (en) 1999-12-29
IL131888A0 (en) 2001-03-19
CA2283891A1 (en) 1998-09-24
WO1998041220A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
US9757422B2 (en) Methods and compositions for regenerating and repairing damaged or aged tissue or organs using nonviable irradiated or lyophilized pluripotent stem cells
US20190276803A1 (en) Method of culturing immune cells, kit for thereof, immune cell cultured medium obtained by same method, cosmetic composition and pharmaceutical composition comprising thereof
AU731086B2 (en) Mononuclear phagocytes and their use to promote axonal regeneration
US9439931B2 (en) Administering umbilical cord blood-derived mesenchymal stem cells to treat nerve injury
CN107708811B (zh) 治疗性汇集的血液凋亡细胞制剂与其用途
JP4100707B2 (ja) 軸索再生を促進する単核貪食細胞の組成物及び使用方法
EP2076588B1 (en) Expansion method for adult stem cells from blood, particularly peripheral blood, and relative application in medical field
JP2015503918A (ja) 同種異系細胞の医療用途の誘導のための方法及び組成物並びに治療的利用
US20120100108A1 (en) Compositions and methods of treating no-option critical limb ischemia (cli)
JP2018520115A (ja) 組織病変治療用組成物
WO2014089397A1 (en) Compositions and methods of treating and preventing pulmonary fibrosis
JP2002500199A (ja) 活性化ｔ細胞、及びそれらの用途
KR20080049917A (ko) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
WO2024243525A1 (en) Compositions, systems, and methods for combinatorial therapies containing fucosylated cells and chemokines and/or scaffolds for autoimmune conditions and regenerative medicine
WO2021032179A1 (zh) 铜绿假单胞菌疫苗在抗烧烫伤感染中的应用
TW202113070A (zh) 間質幹細胞在治療聽力障礙上的醫藥用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090609